New killer for long-destructible H. pylori

H. pylori, the so-called “most successful” pathogen in human history, has been listed by the World Health Organization as one of the 12 “super bacteria” in urgent need of new antibiotics because of its drug resistance. The author learned from Nanjing Medical University on December 8 that the subject of Professor Bi Hongkai of the School of Basic Medicine of the school combined a small zinc linolenate compound, which has an excellent antibacterial effect on Helicobacter pylori. Moreover, it is very “smart”, has a specific role, is not prone to drug resistance, and has high safety. The results were recently published in the journal Antibacterial Agents and Chemotherapy.

Data show that one million new cases of gastric cancer occur every year worldwide, of which 500,000 are new cases in China, and nearly 200,000 people have been killed by gastric cancer. As one of the “culprits” in causing gastric cancer, more than 50% of the world’s population is infected with H. pylori, and the infection rate in China is as high as 60%. The widespread nature of Helicobacter pylori infection, the seriousness of the pathogenicity, and the seriousness of drug resistance have become public problems that endanger human health.

The vitality of H. pylori is very powerful. The human stomach is the only natural host for Helicobacter pylori, and powerful stomach acids cannot kill it. Currently more effective treatments are triple or quadruple therapy with two antibiotics. However, long-term use of antibiotics will cause strains to become resistant, affect the treatment effect, reduce the cure rate, and even cause side effects such as disrupting the balance of the gastrointestinal flora, disrupting metabolism and immunity, and increasing the risk of other diseases.

To overcome the challenge of drug resistance, “exclusive busters” must be developed to eradicate resistant Helicobacter pylori. After the preliminary chemical synthesis, the group screened out the best zinc linolenate. After in vitro and in vivo bacteriostatic effects, pathological repair of gastric mucosa, regulation of inflammatory factors, and evaluation of damage to cells and organs, the compound was found to be safe and effective in killing Helicobacter pylori, and has “specificity” for long It is not easy to produce drug resistance when used, and has very good development potential. The research has obtained national patents.